Cannabis and depression — what studies establish

TL;DR

• Gobbi 2019 (JAMA Psy): adolescent use → OR 1.37 for later depression.
• Suicidal ideation OR 1.50; suicide attempts OR 3.46.
• No robust evidence that cannabis improves depression.
• If in doubt: 143 (Die Dargebotene Hand) or pro-mente-sana.ch.

Self-medication ≠ efficacy

Many patients report short-term mood lift — but long-term regular THC use worsens anhedonia via mesolimbic CB1 down-regulation (Black 2019).

Neurobiological mechanisms and the role of the endocannabinoid system

The endocannabinoid system plays a central role in regulating emotions, stress responses, and synaptic plasticity. Phytannabinoids such as THC mimic the body's own endocannabinoids and bind to receptors in the brain that are also responsible for the release of neurotransmitters such as serotonin and dopamine. While short-term activation of these receptors can be perceived as relaxing, chronic overstimulation by exogenous THC often leads to a disruption of this delicate balance. In the long term, this can impair the body's ability to respond to natural stress and promote depressive episodes.

Another aspect concerns hippocampal neurogenesis, i.e. the formation of new nerve cells in the brain, which is often reduced in depressive disorders. Antidepressants typically promote this process over several weeks. Chronic cannabis use, on the other hand, is suspected of disrupting this regenerative capacity of the brain. In addition, the endocannabinoid system modulates the so-called hypothalamic-pituitary-adrenal axis, which controls the physical stress response. Dysregulation of this axis due to regular consumption can increase susceptibility to affective disorders and reduce resilience to everyday stressors.

• Modulation of neurotransmitters such as serotonin and dopamine by exogenous cannabinoids.
• Influence on synaptic plasticity and neuronal adaptability in the brain.
• Possible impairment of hippocampal neurogenesis in chronic cannabis use.
• Disruption of the hormonal stress axis and reduction of long-term psychological resilience.

Swiss legal framework, medical cannabis, and medical supervision

In Switzerland, the prescription of medical cannabis has been legally facilitated since August 2022, as doctors no longer need to obtain an exceptional permit from the Federal Office of Public Health (FOPH). In cases of severe or treatment-resistant illnesses, medically supervised cannabis therapy may be considered, although the evidence base for depression remains insufficient. Swiss medical professionals usually prescribe such preparations only as an adjunct when established first-line therapies, such as psychotherapy or classic antidepressants, do not show sufficient efficacy. The indication is always determined after a strict individual risk-benefit assessment by the treating specialist.

Patients must also observe the legal framework in everyday life. In Swiss road traffic, a strict zero-tolerance policy applies with a statutory THC limit of 1.5 micrograms per litre of blood, which can lead to unfitness to drive even with medically prescribed cannabis. Furthermore, products with a total THC content of less than one percent do not fall under the Narcotics Act, which is why CBD preparations are freely available on the market. Nevertheless, individuals with depressive symptoms must consult their treating specialists before any intake to prevent dangerous interactions with psychotropic drugs or a worsening of symptoms.

• Facilitated prescription of medical cannabis in Switzerland since August 2022.
• No standard application for depression due to insufficient clinical evidence.
• Strict zero-tolerance regulation in Swiss road traffic with a limit of 1.5 µg/L of blood.
• Differentiation from CBD products below the statutory THC limit of one percent.

Differential diagnosis and the risk of symptom masking

The diagnostic evaluation of depression is significantly complicated by concomitant cannabis use. Individuals often use cannabis as a form of self-medication to temporarily alleviate sleep disorders, inner restlessness, or depressed mood. However, this temporary relief masks the underlying clinical symptoms of depression, often leading to a delayed diagnosis and a later start of treatment. Specialists face the challenge of differentiating between a primary depressive disorder and cannabis-induced depressive symptoms, as the clinical presentations can overlap significantly.

Furthermore, regular use can lead to a lack of motivation that is clinically difficult to distinguish from depressive lethargy. This state complicates active participation in psychotherapeutic measures, which are essential for long-term recovery. Therefore, a structured withdrawal or a significant reduction in use is often the first prerequisite in clinical practice to establish a reliable diagnosis and develop an effective treatment plan. Only in this way can it be assessed which symptoms persist and require targeted psychiatric or psychotherapeutic interventions.

• Complicated diagnosis due to the overlapping of the consequences of consumption and depressive symptoms.
• Risk of delayed therapeutic intervention due to temporary symptom masking.
• Differentiation problems between cannabis-induced lethargy and depressive lack of drive.
• Necessity of a supervised break in consumption to establish a valid clinical finding.

FAQ